Skip to main content

Ongoing FDAEvent 99760 (22 days ago)

New York Embroidery Studio Trinity Non-Surgical Isolation Gown

The isolation gowns may not meet liquid-barrier performance requirements.

Moderate risk

Using it may cause temporary or medically reversible health problems. Serious harm is unlikely.

FDA Class II recall · How risk is rated

What to do

What happened

New York Embroidery Studio, Inc., of Brooklyn, New York, recalled its New York Embroidery Studio Trinity Non-Surgical Isolation Gown, AAMI PB70 Level 2, X-Large, Model Number NYES100-2, because the gowns do not consistently meet the minimum liquid-barrier performance required. The recall began on July 31, 2026, and was added to the FDA's Enforcement Report on September 23, 2026.

The gowns are packaged in inner packs of 10 and 100 gowns per shipping case. The recall covers 5,400 gowns distributed in Connecticut.

Summary by Recall Canary from the FDA notice.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medical device recalls:

  1. A device recall doesn't always mean you must stop using it: it may need to be checked, adjusted or fixed.
  2. Talk to your health care provider before you stop using it.

Is yours affected?

Match the model number, UDI-DI and lot code listed under your product.

  1. New York Embroidery Studio Trinity Non-Surgical Isolation Gown, Aami PB70 Level 2, X-Large.

    Model
    • NYES100-2
    UDI-DI
    • 10860008955149
    Lot
    • B0676

Details

Company began the recall
Sold in

US Nationwide distribution in the state of Connecticut.

Event ID
99760
Recall No.
Z-3259-2026
Company
New York Embroidery Studio, Inc.Brooklyn, New York
Quantity recalled
5,400 gowns
Recall type
Voluntary: Firm initiated
Customers told by
E-Mail
  1. Company began the recall

  2. Added to FDA's Enforcement Report · Classified by FDA

  3. Listed on Recall Canary

  4. In FDA's weekly enforcement report

  5. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 2, 2026 · primary source: U.S. Food and Drug Administration